JOP20200020B1 - ميوتينات إنترليوكين-21 وطرق العلاج - Google Patents

ميوتينات إنترليوكين-21 وطرق العلاج

Info

Publication number
JOP20200020B1
JOP20200020B1 JOP/2020/0020A JOP20200020A JOP20200020B1 JO P20200020 B1 JOP20200020 B1 JO P20200020B1 JO P20200020 A JOP20200020 A JO P20200020A JO P20200020 B1 JOP20200020 B1 JO P20200020B1
Authority
JO
Jordan
Prior art keywords
methods
muteins
interleukin
treatment
mitogens
Prior art date
Application number
JOP/2020/0020A
Other languages
Arabic (ar)
English (en)
Inventor
Zhulun Wang
Neeraj Jagdish Agrawal
Daren Bates
Shunseke Takenaka
Khaled M K Z Ali
Ian Foltz
Gunasekaran Kannan
Marissa Mock
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20200020A1 publication Critical patent/JOP20200020A1/ar
Application granted granted Critical
Publication of JOP20200020B1 publication Critical patent/JOP20200020B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JOP/2020/0020A 2017-08-03 2018-08-03 ميوتينات إنترليوكين-21 وطرق العلاج JOP20200020B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540692P 2017-08-03 2017-08-03
US201862616733P 2018-01-12 2018-01-12
PCT/US2018/045105 WO2019028316A1 (en) 2017-08-03 2018-08-03 INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT

Publications (2)

Publication Number Publication Date
JOP20200020A1 JOP20200020A1 (ar) 2020-02-02
JOP20200020B1 true JOP20200020B1 (ar) 2023-09-17

Family

ID=63350603

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0020A JOP20200020B1 (ar) 2017-08-03 2018-08-03 ميوتينات إنترليوكين-21 وطرق العلاج

Country Status (37)

Country Link
US (2) US11541103B2 (enExample)
EP (2) EP4029877B1 (enExample)
JP (2) JP7079171B2 (enExample)
KR (2) KR102414120B1 (enExample)
CN (2) CN111164100B (enExample)
AU (2) AU2018311079B2 (enExample)
BR (2) BR112020002013B1 (enExample)
CA (1) CA3071376A1 (enExample)
CL (3) CL2020000252A1 (enExample)
CO (1) CO2020001113A2 (enExample)
CR (1) CR20200099A (enExample)
CY (1) CY1125429T1 (enExample)
DK (1) DK3661954T3 (enExample)
ES (2) ES2975221T3 (enExample)
HR (1) HRP20220404T1 (enExample)
HU (1) HUE058233T2 (enExample)
IL (2) IL272137B2 (enExample)
JO (1) JOP20200020B1 (enExample)
LT (1) LT3661954T (enExample)
MA (1) MA56289B1 (enExample)
MX (2) MX2020001328A (enExample)
MY (1) MY195974A (enExample)
PE (2) PE20250757A1 (enExample)
PH (1) PH12020500231A1 (enExample)
PL (1) PL3661954T3 (enExample)
PT (1) PT3661954T (enExample)
RS (1) RS63101B1 (enExample)
SA (2) SA522432917B1 (enExample)
SG (1) SG11202000821SA (enExample)
SI (1) SI3661954T1 (enExample)
SM (1) SMT202200162T1 (enExample)
TN (1) TN2020000015A1 (enExample)
TW (2) TWI844073B (enExample)
UA (1) UA130113C2 (enExample)
UY (1) UY37829A (enExample)
WO (1) WO2019028316A1 (enExample)
ZA (2) ZA202001251B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019033087A1 (en) * 2017-08-11 2019-02-14 Research Development Foundation MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE
WO2019207942A1 (ja) * 2018-04-27 2019-10-31 OTA Takayo 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
EP3827079A1 (en) * 2018-07-25 2021-06-02 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3123338A1 (en) * 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
EP3927740A4 (en) * 2019-02-22 2023-03-01 Anwita Biosciences, Inc. ALBUMIN-BINDING ANTIBODIES AND USE THEREOF
CA3138550A1 (en) * 2019-04-30 2020-11-05 Target Discovery Merger Sub II, LLC Cancer associated antibody compositions and methods of use
AU2020380379A1 (en) * 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
WO2021092719A1 (zh) * 2019-11-11 2021-05-20 王盛典 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白
TW202128961A (zh) 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用
CN111087473B (zh) * 2019-12-11 2022-06-14 上海百英生物科技有限公司 一种SIRPa-Fc-IL21融合蛋白及其应用
PE20231076A1 (es) 2020-05-26 2023-07-17 Boehringer Ingelheim Int Anticuerpos anti-pd-1
JP2023531876A (ja) * 2020-06-30 2023-07-26 ジーアイ イノベーション， インコーポレイテッド 抗ｌａｇ－３抗体とｉｌ－２とを含む融合タンパク質及びその使用
CN111925990B (zh) * 2020-09-02 2022-08-26 北京立康生命科技有限公司 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CA3199086A1 (en) * 2020-10-26 2022-05-05 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
JP2024500232A (ja) * 2020-12-23 2024-01-05 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２１変異体およびその使用
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
AU2022253351A1 (en) * 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
MX2023012724A (es) 2021-04-27 2024-02-08 Amgen Inc Modulación de la calidad de producto de anticuerpos multiespecíficos asimétricos a través del uso de la temperatura.
MX2023013723A (es) 2021-05-19 2024-02-13 Asher Biotherapeutics Inc Polipeptidos de il-21 y construcciones dirigidas.
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2023015298A1 (en) * 2021-08-06 2023-02-09 Amgen Inc. Isolation of therapeutic protein
JP2024536837A (ja) * 2021-09-24 2024-10-08 バイオンシステムズ インコーポレイテッド Ｐｄ－１とｉｌ－２１とを含む融合タンパク質二量体、及びその使用
WO2023052846A2 (en) * 2021-09-30 2023-04-06 Ildong Pharmaceutical Co., Ltd. Immunocytokine containing il-21r mutein
EP4511054A2 (en) * 2022-04-20 2025-02-26 Neptune Biosciences LLC Orthogonal il-21 receptor/cytokine systems
US20250282869A1 (en) * 2022-05-05 2025-09-11 Amgen Inc. Heteromultimer binding dll3 and cd3
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
WO2024002170A1 (en) * 2022-06-29 2024-01-04 Beijing Neox Biotech Limited Il-21 polypeptides and methods of use
CN117645669B (zh) * 2022-08-29 2024-11-01 星奕昂(上海)生物科技有限公司 具有膜结合型il-21的免疫细胞及其制法和应用
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用
WO2024228173A2 (en) * 2023-05-04 2024-11-07 Peptone, Ltd. Engineered cytokines and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
EP4644413A1 (en) * 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
CN119954928B (zh) * 2025-02-12 2025-12-02 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途
CN119978098A (zh) * 2025-02-12 2025-05-13 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途
CN119954929B (zh) * 2025-02-12 2025-12-02 华润生物医药有限公司 Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
KR20010040819A (ko) 1998-02-10 2001-05-15 가마꾸라 아끼오 제어방출형 제제
PL199747B1 (pl) 1998-04-21 2008-10-31 Micromet Ag Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2000040734A1 (en) 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
ATE508635T1 (de) 2001-03-27 2011-05-15 Catherex Inc Virusvektoren und ihre verwendung bei therapeutischen methoden
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002336676A1 (en) 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
WO2004003140A2 (en) 2002-01-18 2004-01-08 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
PT1531850E (pt) 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
US7917208B2 (en) 2002-10-04 2011-03-29 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CN1513993A (zh) * 2002-12-31 2004-07-21 北京博泰迪生物工程科技开发有限公司 中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
CA2538083A1 (en) 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
AU2005250499B2 (en) 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
JP2008533147A (ja) 2005-03-14 2008-08-21 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
CA2604222A1 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
EP1960433A2 (en) 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
ES2409835T3 (es) 2005-11-28 2013-06-28 Zymogenetics, Inc. Antagonistas de IL-21
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
ES2606490T3 (es) 2006-05-08 2017-03-24 Philogen S.P.A. Citocinas dirigidas por anticuerpos para terapia
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
WO2008074863A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
EP4059964A1 (en) 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Cross-species-specific binding domain
SI2520590T1 (sl) 2007-04-03 2018-12-31 Amgen Research (Munich) Gmbh Posebna vezna domena za križanje vrst
KR101034888B1 (ko) 2007-04-19 2011-05-17 동아제약주식회사 지속제어 방출 양상을 갖는 당조절 펩타이드 함유 생분해성고분자 미립구 및 그 제조방법
CN103772502B (zh) 2007-12-07 2017-03-29 津莫吉尼蒂克斯公司 抗人il‑21单克隆抗体
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2010037836A2 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
EP2406282A1 (en) * 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
CN102573922B (zh) 2009-08-17 2015-08-05 罗切格利卡特公司 靶向性免疫缀合物
WO2011051489A2 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
ES2638521T5 (es) 2010-03-05 2021-03-02 Univ Johns Hopkins Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
JP2014511147A (ja) 2011-02-10 2014-05-12 ロシュ グリクアート アーゲー 改善された免疫療法
JP2014517683A (ja) 2011-03-11 2014-07-24 アムジェン インコーポレイテッド 治療抗体を改善する相関突然変異分析の方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN110272484A (zh) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 白蛋白变体
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
PT2753355T (pt) 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
BR112014009925B1 (pt) * 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
WO2013096732A2 (en) 2011-12-23 2013-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
WO2013109904A1 (en) 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
CN108503711A (zh) 2012-04-30 2018-09-07 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
WO2014023679A1 (en) 2012-08-07 2014-02-13 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
CN105518143B (zh) 2013-03-15 2020-02-21 北京凯得尔森生物技术有限公司 融合蛋白分子和它的使用方法
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
WO2015000585A1 (en) 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
JP6704101B2 (ja) 2013-07-11 2020-06-03 ザ・スクリップス・リサーチ・インスティテュート コイルドコイルの免疫グロブリン融合タンパク質およびその組成物
MX370449B (es) 2013-12-12 2019-12-13 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este.
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20160117463A (ko) 2014-02-06 2016-10-10 에프. 호프만-라 로슈 아게 인터루킨-10 면역접합체
MX387323B (es) 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
RS60795B1 (sr) 2014-04-08 2020-10-30 Boston Pharmaceuticals Inc Vezujući molekuli specifični za il-21 i njihove upotrebe
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
WO2016100375A2 (en) 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
CN107249633A (zh) 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
KR20160113452A (ko) 2015-03-20 2016-09-29 (주)엘지하우시스 진공 단열재용 심재 및 진공단열재
CA2993948A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods of use thereof
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US20180221503A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
AU2016305697B2 (en) 2015-08-11 2023-02-02 WuXi Biologics Ireland Limited Novel anti-PD-1 antibodies
CA2993432A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2017055443A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-pd1 antibodies and methods of use
RS63125B1 (sr) 2015-11-03 2022-05-31 Janssen Biotech Inc Antitela koja se specifično vezuju za pd-1 i njihova upotreba
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
CA3009161A1 (en) * 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
EP3400290B1 (en) 2016-01-08 2023-04-05 Replimune Limited Oncolytic virus strain
US20210000921A1 (en) 2016-01-11 2021-01-07 Flagship Pioneering Innovations V. Inc. Methods and compositions for modulating thymic function
PL3411402T3 (pl) 2016-02-03 2022-02-28 Amgen Research (Munich) Gmbh Konstrukty bispecyficznych przeciwciał angażujących komórki T BCMA i CD3
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
EP3411414A4 (en) 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
ES2877568T3 (es) 2016-02-05 2021-11-17 Orionis Biosciences Nv Agentes de unión de Clec9A
EP3430055B1 (en) 2016-03-17 2020-10-28 Oslo Universitetssykehus HF Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
MA44507A (fr) 2016-04-01 2019-02-06 Amgen Inc Récepteurs chimères de flt3 et leurs procédés d'utilisation
CN108350468B (zh) 2016-04-22 2020-10-30 深圳市亦诺微医药科技有限公司 用于癌症治疗的溶瘤性单纯疱疹病毒(oHSV)专性载体及其构建体的构建
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
EP3490583B1 (en) 2016-08-01 2023-11-29 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
AU2017328309B2 (en) 2016-09-14 2020-10-15 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to PD-1 and functional fragment thereof
HRP20250400T1 (hr) 2016-09-21 2025-05-09 Cstone Pharmaceuticals Monoklonska antitijela za programiranu smrt 1 (pd-1)
CN109922822A (zh) 2016-09-23 2019-06-21 昂科赛克医疗公司 调节对检查点抑制剂疗法的应答
CN110392694B (zh) 2016-11-02 2023-08-04 震动疗法股份有限公司 针对pd-1的抗体及其用途
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN107082812B (zh) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
DK3606946T3 (da) 2017-04-03 2022-10-24 Hoffmann La Roche Immunkonjugater af et anti-PD-1-antistof med et muteret IL-2 eller med IL-15
EP3649147A4 (en) 2017-07-03 2021-04-14 Torque Therapeutics, Inc. POLYNUCLEOTIDES CODING IMMUNOSTIMULANT FUSION MOLECULES AND THEIR USES
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
KR20210005872A (ko) 2018-03-28 2021-01-15 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
AU2019251473A1 (en) 2018-04-10 2020-10-22 Amgen Inc. Chimeric receptors to DLL3 and methods of use thereof
WO2019246003A1 (en) 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Anti-mesothelin constructs and uses thereof
EP3856229A1 (en) 2018-09-28 2021-08-04 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
WO2020127369A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1

Also Published As

Publication number Publication date
MA56289B1 (fr) 2022-04-29
TW202342501A (zh) 2023-11-01
BR112020002013B1 (pt) 2023-01-24
CN111164100A (zh) 2020-05-15
JP7079171B2 (ja) 2022-06-01
RS63101B1 (sr) 2022-04-29
PT3661954T (pt) 2022-04-14
AU2018311079B2 (en) 2022-06-23
UA130113C2 (uk) 2025-11-19
JOP20200020A1 (ar) 2020-02-02
CN118126157A (zh) 2024-06-04
PL3661954T3 (pl) 2022-05-16
MY195974A (en) 2023-02-27
EP4029877A1 (en) 2022-07-20
CA3071376A1 (en) 2019-02-07
HUE058233T2 (hu) 2022-07-28
WO2019028316A1 (en) 2019-02-07
HRP20220404T1 (hr) 2022-05-27
SA520411230B1 (ar) 2022-11-08
CR20200099A (es) 2020-07-24
KR102414120B1 (ko) 2022-06-28
BR112020002013A2 (pt) 2020-07-28
SG11202000821SA (en) 2020-02-27
BR122021015266B1 (pt) 2023-01-24
US20230381276A1 (en) 2023-11-30
TW202246308A (zh) 2022-12-01
CY1125429T1 (el) 2024-02-16
MX2023013462A (es) 2023-12-15
CL2024002249A1 (es) 2025-02-21
SI3661954T1 (sl) 2022-05-31
MX2020001328A (es) 2020-03-20
TW201920239A (zh) 2019-06-01
TWI844073B (zh) 2024-06-01
CO2020001113A2 (es) 2020-05-15
PE20250757A1 (es) 2025-03-13
PH12020500231A1 (en) 2021-01-11
IL272137B1 (en) 2024-07-01
PE20200867A1 (es) 2020-08-31
TN2020000015A1 (en) 2021-10-04
AU2018311079A1 (en) 2020-02-13
AU2022228122B2 (en) 2024-05-02
IL312607B2 (en) 2025-08-01
IL272137A (en) 2020-03-31
US20190046611A1 (en) 2019-02-14
TWI798245B (zh) 2023-04-11
SA522432917B1 (ar) 2023-11-05
JP2019033743A (ja) 2019-03-07
JP7531545B2 (ja) 2024-08-09
ZA202001251B (en) 2025-04-30
IL272137B2 (en) 2024-11-01
IL312607B1 (en) 2025-04-01
UY37829A (es) 2019-01-31
KR20220092652A (ko) 2022-07-01
MA56289A (fr) 2020-06-10
CL2020000252A1 (es) 2020-08-21
EP3661954B1 (en) 2022-02-09
ZA202210065B (en) 2025-04-30
ES2975221T3 (es) 2024-07-04
CL2022000300A1 (es) 2022-09-23
DK3661954T3 (da) 2022-04-19
AU2022228122A1 (en) 2022-09-29
US11541103B2 (en) 2023-01-03
ES2910969T3 (es) 2022-05-17
SMT202200162T1 (it) 2022-05-12
EP4029877B1 (en) 2024-01-17
CN111164100B (zh) 2024-03-12
JP2022116099A (ja) 2022-08-09
LT3661954T (lt) 2022-04-11
KR20200035291A (ko) 2020-04-02
EP3661954A1 (en) 2020-06-10
IL312607A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
JOP20200020B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
CY1123028T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
CA3254669A1 (en) Targeted integration of nucleic acids
EA202091710A1 (ru) Антитела против cd73 и способы их применения
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
AR115389A1 (es) Anticuerpo antagonista de cd73
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EA201892774A1 (ru) Антитела
BR112016017986A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos de produção de um anticorpo, de tratamento do câncer, de tratamento de uma doença e de detecção de jagged1 humana em uma amostra biológica, imunoconjugado, formulação farmacêutica e uso do anticorpo
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
MY199683A (en) Anti-pd-1 antibodies
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
UY35250A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos.
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA202090431A1 (ru) Мутеины интерлейкина-21 и способы лечения
EA202091596A1 (ru) Антитела к pd-1 и способы лечения
MX2024002187A (es) Anticuerpos y conjugados de nectina-4.
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения